Literature review: treatment design to overcome anticancer drug resistance

Penulis

  • Baha Udin Pharmacy Magister, Faculty of Mathematics and Natural Science, Universitas Islam Indonesia, Sleman, Yogyakarta, 55584, Indonesia ,
  • Yusransyah Yusransyah Pharmacy Study Program, Sekolah Tinggi Ilmu Kesehatan Salsabila Serang, Serang, Banten, 42211, Indonesia , http://orcid.org/0000-0002-2548-5847 (tidak diautentikasi)
  • Sofi Nurmay Stiani Pharmacy Study Program, Sekolah Tinggi Ilmu Kesehatan Salsabila Serang, Serang, Banten, 42211, Indonesia , http://orcid.org/0000-0002-9703-8835 (tidak diautentikasi)
  • Muhammad Dinta Rizkiana Pharmacy Study Program, Sekolah Tinggi Ilmu Kesehatan Salsabila Serang, Serang, Banten, 42211, Indonesia ,

DOI:

https://doi.org/10.35814/jifi.v22i2.1573

Kata Kunci:

Anti-Cancer, Chemotherapy, Literature Studies, Resistance

Abstrak

One of the main causes of death in the world today is cancer. Chemotherapy is one treatment that cancer patients may utilize. Anticancer medication resistance, which might forecast a rise in treatment failure rates among cancer patients, poses a challenge to the current use of anticancer treatments. Numerous investigators have studied potential approaches to combat anti-cancer medication resistance. The purpose of this literature review is to provide information on treatment planning that can be applied to counteract anti-cancer medication resistance. Cancer is one of the leading causes of death in the modern world. One therapeutic option available to cancer patients is chemotherapy. The current usage of anticancer medicines is challenged by anticancer medication resistance, which may predict an increase in treatment failure rates among cancer patients. Many researchers have looked into possible strategies to fight drug resistance to anti-cancer medications. This review of the literature aims to give information on treatment planning that can be used to combat drug resistance to anti-cancer medications.

Referensi

Unduhan

Diterbitkan

2024-10-31

Terbitan

Vol 22 No 2 (2024): JIFI

Bagian

Articles

Lisensi

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.